This application represents a continuation of our efforts to utilize mouse models to understand the molecular mechanisms of human prostate cancer, as part of the NCI Mouse Models of Human Cancer Consortium. Our team of investigators includes long-standing members of our previous group (Drs. Cory Abate-Shen and Michael Shen), as well as new members (Drs. Andrea Califano and Carlos Cordon-Cardo) who will bring essential expertise in two key areas, systems/computational biology and systems pathology. At the heart of our program is a series of genetically-engineered mouse models of prostate cancer that have been generated and characterized to identify new biomarkers for biochemical recurrence of human prostate cancer, to characterize key signaling pathways responsible for hormone-refractory prostate cancer, and to pursue pre-clinical studies. In the current application, our objective is to use reverse-engineering of regulatory programs in mouse and human prostate cancer to develop accurate molecular interaction maps for human (human Prostate Cancer interactome, hPCi) and mouse (mPCi). We will employ innovative bioinformatics tools that will identify the "drivers" that are causally responsible for tumor progression, as distinct from other discovery approaches that identify "passenger" genes whose expression is simply correlated with a particular cancer phenotype. Thus, the human and mouse PCis will be interrogated using systems biology tools to elucidate key regulators of the genetic pathways that are dysregulated in cancer (Specific Aim 1) and to identify druggable targets that can affect such altered pathways (Specific Aim 2). Candidate key regulatory genes identified by these analyses will be biochemically and functionally validated for their causal role in tumorigenesis and tumor progression, and their relevance for human prostate cancer will be validated using systems pathology approaches. Finally, lead candidate druggable targets will be evaluated as potential therapeutic targets in pre-clinical trial programs, using our in vivo mouse models.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA084294-15
Application #
8532832
Study Section
Special Emphasis Panel (ZCA1-SRLB-Q (M1))
Program Officer
Marks, Cheryl L
Project Start
1999-09-30
Project End
2014-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
15
Fiscal Year
2013
Total Cost
$685,776
Indirect Cost
$259,828
Name
Columbia University (N.Y.)
Department
Urology
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Aytes, Alvaro; Mitrofanova, Antonina; Lefebvre, Celine et al. (2014) Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell 25:638-51
Irshad, Shazia; Abate-Shen, Cory (2013) Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic. Cancer Metastasis Rev 32:109-22
Delto, Joan C; Kobayashi, Takashi; Benson, Mitchell et al. (2013) Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression. Oncotarget 4:269-76
Kobayashi, Takashi; Wang, Jingqiang; Al-Ahmadie, Hikmat et al. (2013) ARF regulates the stability of p16 protein via REGýý-dependent proteasome degradation. Mol Cancer Res 11:828-33
Irshad, Shazia; Bansal, Mukesh; Castillo-Martin, Mireia et al. (2013) A molecular signature predictive of indolent prostate cancer. Sci Transl Med 5:202ra122
Aytes, Alvaro; Mitrofanova, Antonina; Kinkade, Carolyn Waugh et al. (2013) ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer. Proc Natl Acad Sci U S A 110:E3506-15
Jin, Feng; Irshad, Shazia; Yu, Wei et al. (2013) ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity. Mol Cancer Res 11:736-47
Wang, Zhu A; Mitrofanova, Antonina; Bergren, Sarah K et al. (2013) Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. Nat Cell Biol 15:274-83
Wang, Xi; Kruithof-de Julio, Marianna; Economides, Kyriakos D et al. (2009) A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461:495-500
Puzio-Kuter, Anna M; Castillo-Martin, Mireia; Kinkade, Carolyn W et al. (2009) Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 23:675-80

Showing the most recent 10 out of 70 publications